[Skip to Content]
[Skip to Content Landing]
Views 447
Citations 0
Observation
June 3, 2020

The Search for a Uniformly Effective Treatment in Patients With Lupus Miliaris Disseminatus Faciei

Author Affiliations
  • 1Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
  • 2Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
JAMA Dermatol. Published online June 3, 2020. doi:10.1001/jamadermatol.2020.1069

Lupus miliaris disseminatus faciei (LMDF) is an uncommon inflammatory granulomatous dermatosis with possible immune mechanisms, affecting adults between the second and fourth decades of life.1 It presents with multiple asymptomatic, erythematous to yellow-brown papules on the central part of the face and eyelids. Histopathologic test results show perifollicular epithelioid granulomas with caseous necrosis, although a sarcoid granuloma–like appearance has also been reported.2 A few researchers consider LMDF to be a variant of granulomatous rosacea or an inflammatory response to Demodex folliculorum and/or Propionibacterium acnes.1 Although the disease resolves spontaneously within 1 to 2 years, it produces cosmetically disfiguring scars on the face. Treatment response has been unsatisfactory; multiple agents—including tetracyclines, corticosteroids, and isotretinoin—have been tried, with no single uniformly effective treatment.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×